KR102104197B1 - 난소암의 치료를 위한 항혈관신생 요법 - Google Patents

난소암의 치료를 위한 항혈관신생 요법 Download PDF

Info

Publication number
KR102104197B1
KR102104197B1 KR1020187035833A KR20187035833A KR102104197B1 KR 102104197 B1 KR102104197 B1 KR 102104197B1 KR 1020187035833 A KR1020187035833 A KR 1020187035833A KR 20187035833 A KR20187035833 A KR 20187035833A KR 102104197 B1 KR102104197 B1 KR 102104197B1
Authority
KR
South Korea
Prior art keywords
vegf
antibody
cancer
bevacizumab
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187035833A
Other languages
English (en)
Korean (ko)
Other versions
KR102104197B9 (ko
KR20180135101A (ko
Inventor
제이콥 듀퐁
코넬리아 얼
Original Assignee
제넨테크, 인크.
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44476669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102104197(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 제넨테크, 인크., 에프. 호프만-라 로슈 아게 filed Critical 제넨테크, 인크.
Publication of KR20180135101A publication Critical patent/KR20180135101A/ko
Application granted granted Critical
Publication of KR102104197B1 publication Critical patent/KR102104197B1/ko
Publication of KR102104197B9 publication Critical patent/KR102104197B9/ko
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00—Subject matter not provided for in other groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Business, Economics & Management (AREA)
  • Physics & Mathematics (AREA)
  • General Business, Economics & Management (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187035833A 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법 Ceased KR102104197B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US30709510P 2010-02-23 2010-02-23
US61/307,095 2010-02-23
US35123110P 2010-06-03 2010-06-03
US61/351,231 2010-06-03
US36005910P 2010-06-30 2010-06-30
US61/360,059 2010-06-30
US201161439819P 2011-02-04 2011-02-04
US61/439,819 2011-02-04
KR1020187006794A KR20180028561A (ko) 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187006794A Division KR20180028561A (ko) 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197037761A Division KR20190143480A (ko) 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법

Publications (3)

Publication Number Publication Date
KR20180135101A KR20180135101A (ko) 2018-12-19
KR102104197B1 true KR102104197B1 (ko) 2020-04-24
KR102104197B9 KR102104197B9 (ko) 2022-10-21

Family

ID=44476669

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020187035833A Ceased KR102104197B1 (ko) 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법
KR1020187006794A Ceased KR20180028561A (ko) 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법
KR1020197037761A Ceased KR20190143480A (ko) 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법
KR1020127021909A Ceased KR101839161B1 (ko) 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020187006794A Ceased KR20180028561A (ko) 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법
KR1020197037761A Ceased KR20190143480A (ko) 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법
KR1020127021909A Ceased KR101839161B1 (ko) 2010-02-23 2011-02-22 난소암의 치료를 위한 항혈관신생 요법

Country Status (20)

Country Link
US (8) US8778340B2 (https=)
EP (3) EP2539367A2 (https=)
JP (6) JP2013520442A (https=)
KR (4) KR102104197B1 (https=)
CN (3) CN120733043A (https=)
AR (1) AR080244A1 (https=)
AU (5) AU2011221229B2 (https=)
BR (1) BR112012020700A8 (https=)
CA (2) CA2930248A1 (https=)
CL (1) CL2012002326A1 (https=)
CO (1) CO6592072A2 (https=)
IL (2) IL221058B (https=)
MA (1) MA34059B1 (https=)
MX (3) MX369170B (https=)
PH (2) PH12012501681A1 (https=)
RU (1) RU2012140447A (https=)
SG (2) SG10201401123VA (https=)
TW (2) TWI619509B (https=)
UA (1) UA114277C2 (https=)
WO (1) WO2011106300A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
WO2013135602A2 (en) 2012-03-13 2013-09-19 F. Hoffmann-La Roche Ag Combination therapy for the treatment of ovarian cancer
LT3495387T (lt) 2012-07-13 2021-11-25 Roche Glycart Ag Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
SG11201500903XA (en) * 2012-08-07 2015-03-30 Genentech Inc Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US9676863B2 (en) 2014-02-10 2017-06-13 Merck Patent Gmbh Targeted TGFβ inhibitors
US20170112866A1 (en) * 2014-04-04 2017-04-27 Taiho Pharmaceutical Company Limited Anti-tumor agent containing taxane compound, and anti-tumor effect enhancer
CA2946906A1 (en) * 2014-05-07 2015-11-12 Medimmune, Llc Methods of using anti-ang2 antibodies
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016011052A1 (en) 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
CN107106688A (zh) * 2014-11-14 2017-08-29 豪夫迈·罗氏有限公司 预测对vegf拮抗剂的响应
AU2016323968B2 (en) 2015-09-17 2023-07-06 Immunogen, Inc. Therapeutic combinations comprising anti-FOLR1 immunoconjugates
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
TW201713360A (en) * 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
EP3272771A1 (en) * 2016-07-22 2018-01-24 Centre National De La Recherche Scientifique Treatment for use for preventing metastasis in a subject exposed to cancer treatment inducing p38 activation
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CN112165957A (zh) * 2018-03-26 2021-01-01 上海易乐生物技术有限公司 proBDNF调节剂在B细胞相关疾病中的用途
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US20240139316A1 (en) * 2021-03-10 2024-05-02 Canariabio Inc. Use of oregovomab and bevacizumab, paclitaxel, carboplatin for treatment of brca-wild type platinum sensitive recurrent
CN113244388A (zh) * 2021-07-01 2021-08-13 江苏先声药业有限公司 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
EP4504260A1 (en) * 2022-04-04 2025-02-12 Merck Sharp & Dohme LLC Methods for treating cancer, an infectious disease or an infection using a combination of a tigit antagonist, a pd-1 antagonist, and a vegf antagonist

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US991302A (en) * 1910-03-28 1911-05-02 Frederick G Hepburn Waste-supporter.
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
BR9207175A (pt) 1992-10-28 1995-12-12 Genentech Inc Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
EP2338915A3 (en) 1997-04-07 2011-10-12 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ATE296315T1 (de) 1997-06-24 2005-06-15 Genentech Inc Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
MXPA05012723A (es) * 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
RS52213B (sr) 2004-09-03 2012-10-31 Genentech, Inc. Humanizovani anti-beta7 antagonisti i njihove primene
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
CN101889025B (zh) * 2007-10-30 2013-11-13 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
KR101807319B1 (ko) 2008-11-22 2017-12-11 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Clinical Oncology. 1 January 2010, 28(1):154-159.*

Also Published As

Publication number Publication date
TW201526912A (zh) 2015-07-16
US20230226179A1 (en) 2023-07-20
EP3696194A1 (en) 2020-08-19
CN110227154A (zh) 2019-09-13
US20110206662A1 (en) 2011-08-25
CA2787952C (en) 2016-07-26
KR102104197B9 (ko) 2022-10-21
US20160279241A1 (en) 2016-09-29
AU2017204320A1 (en) 2017-07-13
AU2017204320B2 (en) 2019-02-21
JP2020196719A (ja) 2020-12-10
CN120733043A (zh) 2025-10-03
AU2019210484A1 (en) 2019-08-15
MA34059B1 (fr) 2013-03-05
TWI619509B (zh) 2018-04-01
AU2015210479A1 (en) 2015-09-03
EP3064509A3 (en) 2016-11-02
JP6184733B2 (ja) 2017-08-23
IL221058B (en) 2018-04-30
CO6592072A2 (es) 2013-01-02
KR20180028561A (ko) 2018-03-16
US20140178371A1 (en) 2014-06-26
AU2011221229A1 (en) 2012-08-16
IL258612A (en) 2018-06-28
MX369170B (es) 2019-10-30
AR080244A1 (es) 2012-03-21
AU2019203466A1 (en) 2019-06-06
PH12012501681A1 (en) 2012-11-05
EP3064509A2 (en) 2016-09-07
CL2012002326A1 (es) 2012-11-30
TWI457135B (zh) 2014-10-21
KR101839161B9 (ko) 2022-10-18
US20170143826A1 (en) 2017-05-25
KR101839161B1 (ko) 2018-03-16
BR112012020700A2 (pt) 2017-03-21
US20180344847A1 (en) 2018-12-06
CA2930248A1 (en) 2011-09-01
KR20190143480A (ko) 2019-12-30
SG183414A1 (en) 2012-09-27
JP2013173775A (ja) 2013-09-05
CN103237810A (zh) 2013-08-07
US20250177522A1 (en) 2025-06-05
MX2019000425A (es) 2023-04-27
JP2013520442A (ja) 2013-06-06
KR20130010884A (ko) 2013-01-29
KR20180135101A (ko) 2018-12-19
JP2016020354A (ja) 2016-02-04
UA114277C2 (uk) 2017-05-25
RU2012140447A (ru) 2014-03-27
US20210052728A1 (en) 2021-02-25
BR112012020700A8 (pt) 2018-01-02
SG10201401123VA (en) 2014-08-28
WO2011106300A2 (en) 2011-09-01
JP2018199683A (ja) 2018-12-20
MX2012009554A (es) 2012-11-23
US8778340B2 (en) 2014-07-15
JP2017193551A (ja) 2017-10-26
TW201138819A (en) 2011-11-16
AU2011221229B2 (en) 2015-06-18
PH12016501728A1 (en) 2018-02-12
WO2011106300A3 (en) 2011-12-15
CA2787952A1 (en) 2011-09-01
EP2539367A2 (en) 2013-01-02
IL258612B (en) 2022-01-01

Similar Documents

Publication Publication Date Title
US20250177522A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
US20200148756A1 (en) Anti-angiogenesis therapy for the treatment of previously treated breast cancer
US20150071924A1 (en) Anti-Angiogenesis Therapy for the Treatment of Previously Treated Breast Cancer
US20220195027A1 (en) Anti-angiogenesis therapy for the treatment of previously treated breast cancer
HK40013836A (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
HK1183046A (en) Anti-angiogenesis therapy for the treatment of ovarian cancer

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20181210

Application number text: 1020187006794

Filing date: 20180308

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190109

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190211

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190923

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190211

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20191220

Application number text: 1020187006794

Filing date: 20180308

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190923

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190812

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20200120

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20191223

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190923

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20190812

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200417

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200417

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Patent event date: 20210810

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20200417

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20210810

Decision date: 20220429

Appeal identifier: 2021100002402

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Patent event date: 20210824

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20200417

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20210824

Decision date: 20220913

Appeal identifier: 2021100002546

J301 Trial decision

Free format text: TRIAL NUMBER: 2021100002402; TRIAL DECISION FOR INVALIDATION REQUESTED 20210810

Effective date: 20220429

PJ1301 Trial decision

Patent event code: PJ13011S05D

Patent event date: 20220429

Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design)

Appeal kind category: Invalidation

Request date: 20210810

Decision date: 20220429

Appeal identifier: 2021100002402

PC2102 Extinguishment

Termination category: Others

Termination date: 20221012

J2X1 Appeal (before the patent court)

Free format text: TRIAL NUMBER: 2022200003946; INVALIDATION

PJ2001 Appeal

Patent event date: 20220429

Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design)

Patent event code: PJ20011S05I

Appeal kind category: Invalidation

Decision date: 20220920

Appeal identifier: 2022200003946

Request date: 20220705

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20220913

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2021100002546

Request date: 20210824

Appeal kind category: Invalidation

Decision date: 20220913

J122 Written withdrawal of action (patent court)
PJ1202 Withdrawal of action (patent court)

Patent event code: PJ12021R01D

Patent event date: 20221011

Comment text: Written Withdrawal of Action

Decision date: 20220920

Request date: 20220705

Appeal identifier: 2022200003946

Appeal kind category: Invalidation

PG1701 Publication of correction

Publication date: 20221021